FDA extends review of Vitrase by 90 days

Irvine, CA-The FDA is extending its review of ISTA Pharmaceuticals Inc.'s new drug application for Vitrase for use as a spreading agent by 90 days to allow for a full review.

Related Content:

Pharmacy

Comparable conscious sedation methods address individual patient needs

Investigators uncover health care disparities among US patients

Investigators zoom in on future of dry eye treatment